Fotagliptin Plus Metformin Enhances Glycemic Control in T2D
Addition of fotagliptin to metformin significantly reduced A1c levels in patients with type 2 diabetes (T2D) compared with placebo plus metformin without increasing the incidence of hypoglycemic events.
METHODOLOGY:
Previous research indicated that fotagliptin, a dipeptidyl peptidase 4 inhibitor, provided superior glycemic control than placebo in patients with T2D.
Researchers conducted a randomized controlled trial across 53 outpatient clinics in China to evaluate the efficacy and safety of fotagliptin as an add-on to metformin in patients with T2D.
They included 402 patients with T2D (mean age, 55.1 years; mean A1c level, 8.09%; 59% men) who underwent dietary and exercise interventions and received a stable dose of ≥ 1500 mg/d metformin for at least 8 weeks before screening.
Patients were randomly assigned in a 2:1 ratio to receive either fotagliptin 12 mg once daily or placebo in addition to a stable dose of metformin for 24 weeks during the double-blind treatment. Afterward, all patients received fotagliptin 12 mg once daily as part of the open-label fotagliptin treatment until the end of 52 weeks.
The primary endpoint was a change in the A1c level from baseline to week 24.
TAKEAWAY:
At week 24, patients on metformin plus fotagliptin had least square mean change in the A1c level of -0.81% compared with -0.28% in those on metformin plus placebo, with an estimated treatment difference of -0.53% (P < .001).
The A1c target of < 7.0% was achieved by 38.7% of patients on metformin plus fotagliptin compared with 16.9% of patients on metformin plus placebo (P < .0001), with similar results observed for the A1c target of ≤ 6.5% (P < .0001).
In either group, the incidence of treatment-emergent adverse events leading to drug discontinuation was low.
Hypoglycemic events were relatively less frequent in both groups and were considered mild to moderate.
IN PRACTICE:
'In patients with T2D, who were treated with metformin, add-on with fotagliptin 12 mg once daily achieved a superior and clinically meaningful decrease in HbA1c compared with placebo,' the authors concluded.
SOURCE:
This study was led by Nan Yu, MD, Peking University First Hospital, Beijing, China. It was published online in Diabetes, Obesity and Metabolism.
LIMITATIONS:
This study included only Chinese patients with T2D, which may suggest selective bias. The duration of this study was not long enough to assess cardiovascular outcomes or benefits.
DISCLOSURES:
This study was supported by Shenzhen Salubris Pharmaceuticals Co., Ltd, with partial funding from the Shenzhen Science and Technology Program for Undertaking the National Science and Technology Major Project. One author reported being an employee of Shenzhen Salubris Pharmaceuticals Co., Ltd.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
Patients frustrated after Allina Health shuts down St. Paul pain clinic
The recent closing of a St. Paul, Minnesota, pain clinic is causing both physical and emotional headaches for patients. In a letter to patients sent earlier this summer, Allina Health announced the permanent closure of the United Pain Center, effective July 25. According to a spokeswoman, the closure was a result of "significant staffing issues," but the health system is "actively supporting our United Pain Center patients during this transition and working with impacted employees to help them transition." The letter sent to patients also offers six other pain management providers. "Allina Health's decisions to change services are part of an effort to ensure long-term sustainability and maintain excellence in care delivery for the patients and communities we serve," the letter said. "The health care industry, including Allina Health, continues to navigate current financial pressures related to the rising cost to deliver care, falling reimbursements, and the expected impacts of funding cuts for critical health care programs like Medicaid." Colleen Zufall, of Isanti, is among the affected patients, and she said it's been difficult to move forward. "I don't want to be asking doctors all over the place to give me narcotics because then they think you're a drug seeker," Zufall said. "My pill count was always right on target. I never asked for anything early or extra. I never said I needed a higher dose." Minnesota statutes offer protections for patients who don't want to transition off their meds and also for providers who wish to support them. "Minnesota providers shouldn't have the fear because it's all about doing what the patient needs," Dr. Tim Hess, a pain management physician and advocate, told WCCO News. "You're not alone. Don't take this alone. Reach out. Do something. Help a family member. Remember the chance of addiction or substance use disorder in a patient without a history is only about 2% or less. It's way less than people think by the literature." While the closure of the pain center is the first of its kind locally, it does follow a trend of health systems citing costs and staffing to cut services. A months-long WCCO investigation earlier this year found 19 hospitals in Minnesota slashing or relocating services since 2022, and they include everything from obstetrics to surgeries to mental health and beyond.
Bloomberg
an hour ago
- Bloomberg
Pop Mart, Health-Care Stocks Lead Hang Seng Index Contenders
Hang Seng Indexes Co. is likely adding Labubu doll-maker Pop Mart International Group Ltd. and several health-care firms to its Hong Kong stock benchmark, analysts say. Pop Mart has been a frequent contender for inclusion in the Hang Seng Index, with its market capitalization more than tripling this year amid strong demand for its toys and figurines. Health-care stocks have also gained momentum, driven by breakthroughs and overseas partnerships that have lifted sector performance. The results of the quarterly review are expected to be released after the market closes on Friday.
Yahoo
2 hours ago
- Yahoo
Government approves new safety standards for water beads to prevent the risk of injuries to small children
The popular sensory toy can cause serious, even life-threatening, injuries if ingested. The Consumer Product Safety Commission on Wednesday approved new standards for water beads, a popular toy that poses a risk to small children if ingested. Water beads are small, colorful pellets that can be as little as a pinhead when dry but expand when they come in contact with water. Typically, they grow to about the size of a marble. Their slippery, squishy texture has made them a popular element in sensory play for young children. The risk comes when a child swallows them or sticks them in an ear or nose. Some water beads, particularly versions made in China that the commission says have 'flooded' the U.S. market, can expand to as much as 100 times their original size. Ingested water beads can continue growing inside the body, causing serious, even life-threatening, complications. An expanding water bead can also pose a choking risk. Beads inserted into a child's ear canal can cause permanent hearing loss. Some beads are also made with chemicals that are known to cause cancer. Between 2017 and 2022, there were an estimated 6,300 water bead-related injuries treated at emergency rooms across the U.S., according to the commission. At least one death of a 10-month-old girl was reported in 2023. Earlier this year, a mother whose toddler had to have emergency surgery after ingesting water beads issued a warning about the toys during an interview with CBS News. 'During surgery, they found the water beads had caused a blockage inside of her small intestine,' she said. 'Because the water beads were marketed as non-toxic eco-friendly and biodegradable, everybody thought that she would be fine.' The new safety standards will set a maximum size for any water bead toys sold in the U.S., establish limits on the amount of cancer-causing chemicals they can contain and require 'strongly worded, easily seen' warning labels on all water bead toys. They will only apply to products that are specifically marketed to children. Water beads intended for use in home crafts or gardens will not be subject to the new rules. These standards have been a point of contention within the commission, which has viewed water beads as a safety risk for years. Last month, one of its members, Richard Trumka, Jr., publicly accused the commission's Trump-appointed acting chair of blocking the new rules from going forward without offering an explanation. 'Children's lives are too important for inaction,' Trumka, Jr. said in a public statement at the time. 'It's time to get off the sidelines and start working for consumer safety.' The commission recommends that water beads be removed from any environment where small children may be present, that they be stored in a secure container and that parents pay extra attention when cleaning them up to ensure no beads are left behind in a place that a child could reach. Solve the daily Crossword
